News
MDXH
0.1401
-5.97%
-0.0089
Weekly Report: what happened at MDXH last week (1109-1113)?
Weekly Report · 2d ago
MDxHealth Earnings Call Highlights Recovery Plan Amid Setbacks
TipRanks · 4d ago
TD Cowen Keeps Their Buy Rating on MDxHealth (MDXH)
TipRanks · 5d ago
MDxHealth SA GAAP EPS of -$0.16 misses by $0.07, revenue of $22.71M misses by $5.52M
Seeking Alpha · 5d ago
MDxHealth Reports Third-Quarter Results Amid Commercial Restructuring
TipRanks · 6d ago
Weekly Report: what happened at MDXH last week (1102-1106)?
Weekly Report · 11/09 09:12
Weekly Report: what happened at MDXH last week (1026-1030)?
Weekly Report · 11/02 09:12
MDxHealth Calls November Extraordinary Meeting to Approve Reverse Stock Split
TipRanks · 10/30 21:13
Weekly Report: what happened at MDXH last week (1019-1023)?
Weekly Report · 10/26 09:12
MDxHealth downgraded to Neutral from Buy at BTIG
TipRanks · 10/19 10:30
Weekly Report: what happened at MDXH last week (1012-1016)?
Weekly Report · 10/19 09:12
Craig-Hallum downgrades MDxHealth after revenue miss, suspension of guidance
TipRanks · 10/16 13:15
MDxHealth downgraded to Hold from Buy at Lake Street
TipRanks · 10/16 12:41
MDxHealth downgraded to Hold from Buy at Craig-Hallum
TipRanks · 10/16 11:15
MDxHealth Cuts 2026 Guidance After Q3 Revenue Miss and Sales-Force Disruption
TipRanks · 10/16 10:42
Closing Bell Movers: JB Hunt slips after Q3 results
TipRanks · 10/15 23:25
MDxHealth SA reports Preliminary Q3 results
Seeking Alpha · 10/15 20:28
MDxHealth suspends FY26 revenue guidance of $110M-$115M
TipRanks · 10/15 20:16
Weekly Report: what happened at MDXH last week (1005-1009)?
Weekly Report · 10/12 09:13
Weekly Report: what happened at MDXH last week (0928-1002)?
Weekly Report · 10/05 09:13
More
Webull provides a variety of real-time MDXH stock news. You can receive the latest news about Mdxhealth Sa through multiple platforms. This information may help you make smarter investment decisions.
About MDXH
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.